

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)**Search Results -**

Term	Documents
(3 NEAR50 7).USPT.	1

Database: **US Patents Full-Text Database**
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Refine Search:

13 near50 17

[Clear](#)**Search History****Today's Date: 9/10/2000**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT	13 near50 17	1	L8
USPT	extracellular	14409	L7
USPT	13 near50 14	2	L6
USPT	13 (50a) 14	0	L5
USPT	vascular endothelial cell\$1 or neo-vasculature or vasculature or neovasculature or angiogenesis	6770	L4
USPT	11 near50 12	46	L3
USPT	cancer or cancerous or malignan\$4 or neoplas\$3 or tumor or tumour	54749	L2
USPT	psma or (prostate specific membrane antigen)	66	L1

(FILE 'HOME' ENTERED AT 09:38:32 ON 10 SEP 2000)

FILE 'MEDLINE, EMBASE, CAPLUS, CANCERLIT, SCISEARCH, TOXLINE, BIOSIS'
ENTERED AT 09:38:54 ON 10 SEP 2000

L1 1130 S PSMA OR PROSTATE SPECIFIC MEMBRANE ANTIGEN
L2 5488163 S CANCER OR CANCEROUS OR MALIGNAN#### OR NEOPLAS### OR TUMOR
OR
L3 664 S L1 (30A) L2
L4 134377 S VASCULAR ENDOTHELIAL CELL# OR NEO-VASCULATURE OR
NEOVASCULATU
L5 34 S L3 (30A) L4
L6 14 DUP REM L5 (20 DUPLICATES REMOVED)
L7 580503 S EXTRACELLULAR
L8 50 S L7 (30A) L3
L9 16 DUP REM L8 (34 DUPLICATES REMOVED)
L10 28 S L6 OR L9

bad date

L10 ANSWER 4 OF 6 MEDLINE
AN 1999057588 MEDLINE
DN 99057588
TI Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene.
AU O'Keefe D S; Su S L; Bacich D J; Horiguchi Y; Luo Y; Powell C T; Zandvliet
D; Russell P J; Molloy P L; Nowak N J; Shows T B; Mullins C; Vonder Haar
R
A; Fair W R; Heston W D
CS Urologic Oncology Research Laboratory, Molecular Pharmacology and Therapeutics Division, Sloan-Kettering Institute for Cancer Research, Box 334, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021, USA.
NC DK/CA 47650 (NIDDK)
SO BIOCHIMICA ET BIOPHYSICA ACTA, (1998 Nov 26) 1443 (1-2) 113-27.
Journal code: A0W. ISSN: 0006-3002.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
OS GENBANK-AF007544
EM 199904
AB Prostate-specific membrane antigen (PSMA) is a 100 kDa type II transmembrane protein with folate hydrolase and NAALAdase activity. **PSMA** is highly expressed in prostate cancer and the **vasculature** of most solid tumors, and is currently the target of a number of diagnostic and therapeutic strategies. **PSMA** is also expressed in the brain, and is involved in conversion of the major neurotransmitter NAAG (N-acetyl-aspartyl glutamate) to NAA. . .

IDS

0 ANSWER 5 OF 6 MEDLINE

DUPLICATE 2

AN 1999035256 MEDLINE

DN 99035256

TI Prostate-specific membrane antigen expression in normal and malignant human tissues.

AU Silver D A; Pellicer I; Fair W R; Heston W D; Cordon-Cardo C

CS Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

NC DK/CA 47650 (NIDDK)

CA09501 (NCI)

SO CLINICAL CANCER RESEARCH, (1997 Jan) 3 (1) 81-5.

Journal code: C2H. ISSN: 1078-0432.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199904

AB . . . prostate cancer suggests that expression of this molecule may be linked to the degree of tumor differentiation. The neoexpression of **PSMA** in endothelial cells of capillary beds in certain tumors may be related to tumor **angiogenesis** and suggests a potential mechanism for specific targeting of tumor neovasculature.

bad date

L14 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2000 ACS DUPLICATE 4
AN 1999:743282 CAPLUS
DN 132:76781
TI Prostate-specific membrane antigen: Much more than a prostate cancer marker
AU Chang, Sam S.; Gaudin, Paul B.; Reuter, Victor E.; O'Keefe, Denise S.; Bacich, Dean J.; Heston, W. D. W.
CS George M. O'Brien Urology Research Center, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
SO Mol. Urol. (1999), 3(3), 313-319
CODEN: MOURFE; ISSN: 1091-5362
PB Mary Ann Liebert, Inc.
DT Journal; General Review
LA English
RE.CNT 37
RE
(4) Carter, R; Proc Natl Acad Sci USA 1996, V93, P749 CAPLUS
(7) Ellis, L; Eur J Cancer 1996, V32A, P2451 CAPLUS
(11) Grauer, L; Cancer Res 1998, V58, P4787 CAPLUS
(17) Kawakami, M; Cancer Res 1997, V57, P2321 CAPLUS
(18) Leek, J; Br J Cancer 1995, V72, P583 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT
AB A review with 37 refs. Prostate cancer continues to be the most common cancer and second leading cause of cancer-related death among men. The use of markers, particularly serum-based prostate specific antigen (PSA), has contributed to the rapid rise in diagnosed cases in the late 1980s and early 1990s, but new diagnostic and possible therapeutic markers are needed and are currently being evaluated. One of these, prostate-specific membrane antigen (PSMA), is an approx. 100-kDa type II transmembrane protein originally thought to be highly selectively expressed in all types of prostatic tissue, with expression being upregulated in androgen-depleted or androgen-independent states. The radioimmunoconjugate form of the anti-PSMA monoclonal antibody (mAb) 7E11 is currently being used to diagnose prostate cancer metastasis and recurrence. In addn., Phase I and II trials have started utilizing PSMA in different therapeutic ways, with promising results. Recent exciting work has demonstrated **PSMA** expression in endothelial cells of vessels restricted to the tumor-assocd. **neovasculature**. This finding expands the possible beneficial uses of PSMA, as new anti-PSMA mAbs continue to be developed.

L10 ANSWER 11 OF 28 MEDLINE
AN 97265694 MEDLINE
DN 97265694
TI Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line.
AU Troyer J K; Beckett M L; Wright G L Jr
CS Department of Microbiology and Immunology, Virginia Prostate Center, Eastern Virginia Medical School, Norfolk 23501, USA.
SO PROSTATE, (1997 Mar 1) 30 (4) 232-42.
Journal code: PB4. ISSN: 0270-4137.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 199707
EW 19970703
AB . . . antibody-directed imaging with MAb 7E11-C5 only becomes accessible upon apoptosis or necrosis. This further suggests that antibodies directed at the **extracellular** domain may enhance the sensitivity of antibody-directed imaging and therapy of prostate carcinomas by recognizing surface epitopes of **PSMA** on living

IDS

L10 ANSWER 12 OF 28 MEDLINE
AN 96186631 MEDLINE
DN 96186631
TI Measurement of prostate-specific membrane antigen in the serum with a new antibody.
AU Murphy G P; Tino W T; Holmes E H; Boynton A L; Erickson S J; Bowes V A; Barren R J; Tjoa B A; Misrock S L; Ragde H; Kenny G M
CS Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, Washington, USA.
SO PROSTATE, (1996 Apr) 28 (4) 266-71.
Journal code: PB4. ISSN: 0270-4137.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 199607
AB . . . prostatic epithelial cells, and is increased in its expression in

the presence of a hormone refractory state associated with prostatic **cancer**. This report confirms these results and further documents the presence of the monoclonal antibody 3F5.4G6, which reacts with the **extracellular** domain of **PSMA**. This region of **PSMA** is also an element present in a truncated version of the

L10 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2000 ACS

AN 1997:650296 CAPLUS

DN 127:318125

TI Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen

IN Murphy, Gerald P.; Boynton, Alton L.; Holmes, Eric H.; Tino, William T.

PA Pacific Northwest Cancer Foundation, USA

SO PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9735616	A1	19971002	WO 1997-US5214	19970325
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	CA 2250141	AA	19971002	CA 1997-2250141	19970325
	AU 9725552	A1	19971017	AU 1997-25552	19970325
	EP 914155	A1	19990512	EP 1997-917121	19970325
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			

PRAI US 1996-621399 19960325

WO 1997-US5214 19970325

AB The present invention relates to monoclonal antibodies that bind to the **extracellular** domain of **prostate specific membrane antigen (PSMA)**, hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of **cancer**. In particular, it relates to three monoclonal antibodies reactive with PSMA expressed on the cell surface and in sera of prostate cancer patients. Addnl., the present invention relates to a novel protein variant (PSM') of PSMA detected by

an antibody of the invention. The hydrolase activity of PSMA and PSM' allows

the use of an immunoenzymic assay for their detection.

IT Diagnosis

Prognosis

(prostate **cancer**; monoclonal antibodies specific for the **extracellular** domain of **prostate specific** me